CIPLA — BREATHING LIFE INTO THE NEXT GROWTH CYCLE 💊🚀

Some companies chase trends. Cipla has spent decades building expertise in medicines people depend on every day. Now, its next opportunity lies in chronic care, complex generics and global expansion. FY26 delivered ₹28,163 crore in revenue and approximately ₹3,862 crore in consolidated profit after tax. The business continues to build on its established respiratory franchise while expanding across chronic therapies and international markets.  And India remains a key growth engine. In Q1 FY27, domestic revenue reached a record ₹3,452 crore, up 12% YoY. Branded prescriptions grew 15.4%, led by respiratory, diabetes and cardiac therapies. Its flagship inhalation brand Foracort crossed ₹1,000 crore in revenue. But the bigger opportunity extends beyond India. Cipla operates across 69 markets, with a portfolio spanning respiratory medicines, generics, oncology and other therapies. Its differentiated products and complex generics provide avenues to expand internationally. The next growth drivers? Respiratory → Strong brand franchise Chronic care → Recurring prescriptions Complex generics → Higher-value opportunities New launches → Potential revenue growth Global markets → Broader reach Yet, there is a catch. Q1 FY27 consolidated revenue grew just 2.3% to ₹7,119 crore, while profit fell 39% to ₹789 crore. North American revenue dropped 28% to $162 million, reflecting a high base in the previous year and weaker contribution from certain products. That makes the next phase about execution. Can new launches replace declining product contributions? Can the US business recover? Can Cipla sustain domestic growth while protecting margins? These are the questions that matter. Cipla has the brands, the distribution and the pharmaceutical expertise. The challenge is converting those strengths into consistent earnings growth. Healthcare demand doesn't disappear when market sentiment changes.